CD4 and myeloid sarcoma: Recent studies have found that vitamin D3 supplemented at a dose of 10,400 IU was tolerable and safe in MS patients, and mediated pleiotropic immunomodulatory functions in vivo, such as reduction of memory effector CD4+ T cells, decreased production of IL-17 by CD4+ T cells and simultaneous central naïve and memory CD4+ T cells increase [70].